All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
U.S. FDA grants Fast Track designation to DSP-5336 for the treatment of R/R AML
Bookmark this article
DSP-5336, an oral inhibitor of the menin and mixed-lineage leukemia (MLL) interaction, for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) with a KMT2A rearrangement.1
DSP-5336 is currently under investigation as part of a phase I/II study in patients with relapsed/refractory AML.1 The latest data from this study were presented at the European Hematology Association (EHA) 2024 Hybrid Congress. Data presented highlighted an objective response rate of 57%, which included responses in patients with both nucleophosmin 1 (NPM1) mutation and KMT2A (MLL) rearrangement.1 A complete remission or complete with partial hematologic recovery was observed in 24% of patients.1 There were no dose-limiting toxicities observed, nor cardiac signals or treatment-related discontinuations/deaths.1
- PR Newswire. Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia. https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-that-dsp-5336-has-received-fda-fast-track-designation-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-302196812.html. Published July 15, 2024. Accessed July 16, 2024.
More about...
Your opinion matters
3 votes - 19 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox